IL2 and neoplasm: Accordingly, targeting Th2 polarized T cells with the anti-CD30-IL12-IL2 dual cytokine fusion protein may additionally modulate the tumor-environment of Hodgkin's lymphoma by shifting T cells to Th1 reactivity.